Methodological issues in the design of paediatric pharmacokinetic studies

Pharmaceutical Medicine

Volumn 26, Issue 1, 2012, Pages 13-22

  Burckart, Gilbert J ^a   Estes, Kristina E ^a   Leong, Ruby ^a   Mulugeta, Yeruk ^a   Tandon, Veneeta ^a   Wang, Jian ^a   Abernethy, Darrell R ^a   Jadhav, Pravin R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biological proteins; Children; Clinical pharmacokinetics; Clinical trial design; Data collection; Dose prediction; Ethics; Food and Drug Administration; Pharmacokinetic modelling; Pharmacokinetics; Population pharmacokinetics; Therapeutic use

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CISAPRIDE; DICLOFENAC; ETANERCEPT; GENTAMICIN; MIDAZOLAM; OMEPRAZOLE; PHENYTOIN; THEOPHYLLINE; VALGANCICLOVIR; VANCOMYCIN; WARFARIN; ZOLPIDEM;

ADULT DISEASE; AREA UNDER THE CURVE; CHILDHOOD DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFORMATION; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; PEDIATRICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSORIASIS; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW;

EID: 84862910007     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.2165/11598510-000000000-00000     Document Type: Review

References (53)

1. US Food and Drug Administration. Medical, statistical, and clinical phar-macology reviewsofpediatric studies conductedunder section 505A and 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA), 2011 online. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Development Resources/UCM049872 Accessed 2011 Oct 27
2. US Food and Drug Administration. Breakdown of FDAAA completed pe-diatric studies, 2011 online. Available from URL: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ucm190622.htm Accessed 2011 Oct 27
3. Benjamin Jr DK, Smith PB, Jadhav P, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 2008; 51 (4): 834-40 (Pubitemid 351654692)
4. US Food and Drug Administration. Guidance for industry: exposure-response relationships. Study design, data analysis, and regulatory applications, 2003 online. Available from URL: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm072109.pdf Accessed 2011 Oct 27
5. Madabushi R, Cox DS, Hossain M, et al. Pharmacokinetic and pharmaco-dynamic basis for effective argatroban dosinginpaediatrics.J Clin Pharmacol 2011; 51 (1): 19-28
6. Code of Federal Regulations. Subpart D: additional safeguards for children in clinical investigations. Title 21, vol. 1. Rev. 2011 Apr 1; 21CFR50 online. Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1&subpartNode=21:1.0.1.1.19.4 Accessed 2011 Nov 16
7. US Health and Human Services Office of Human Protection. Advanced Notice of Proposed Rulemaking (ANPRM) for revisions to the common rule: comparison of current rule requirements and proposed changes, 2011 online. Available from URL: at: http://www.hhs.gov/ohrp/humansubjects/an prmchangetable.pdf.pdf Accessed 2011 Oct 27
8. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98 (4): 833-8 (Pubitemid 36576310)
9. Rodriguez W, Selen A, Avant D, et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 2008; 121 (3): 530-9
10. Holford N. Dosing in children. Clin Pharmacol Ther 2010; 87 (3): 367-70
11. Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009; 29 (6): 680-90
12. Walvoord EC, De La Pena A, Park S, et al. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharma-cokinetics, pharmacodynamics, and safety. J Clin Endocrinol Metab 2009; 94 (6): 2052-9
13. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009; 28 (5): 412-5
14. Zuppa AF, Mondick JT, Davis L, et al. Population pharmacokinetics of ke-torolac in neonates and young infants. Am J Ther 2009; 16 (2): 143-6
15. Cross SJ, Rodman JH, Lindsey JC, et al. Abacavir and metabolite pharma-cokinetics in HIV-1-infected children and adolescents. J Acquir Immune Defic Syndr 2009; 51 (1): 54-9
16. Saez-Llorens X, Yogev R, Arguedas A, et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009; 53 (5): 1912-20
17. Ren Y, Nuttall JJC, Eley BS, et al. Effect of rifampicin on efavirenz pharma-cokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009; 50 (5): 439-43
18. Chadwick EG, Pinto J, Yogev R, et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J 2009; 28 (3): 215-9
19. Van Der Flier M, Verweel G, Van Der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. Antiviral Ther 2008; 13 (8): 1087-90
20. Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110 (2): 284-94
21. Ghio L, Ferraresso M, Zacchello G, et al. Longitudinal evaluation of myco-phenolic acid pharmacokinetics in pediatric kidney transplant recipients: the role of post-transplant clinical and therapeutic variables. Clin Transplant 2009; 23 (2): 264-70
22. Wang Y, Jadhav PR, Lala M, et al. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. Epub 2011 Dec 12
23. Wang LH, Wiznia AA, Rathore MH, et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48 (1): 183-91 (Pubitemid 38040196)
24. Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of suma-triptan nasal spray in children. J Clin Pharmacol 2004; 44 (4): 359-67 (Pubitemid 38392009)
25. Dixon R, Engleman K, Kemp J, et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol 1999; 9 (1): 35-42 (Pubitemid 29230951)
26. De Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today 2009; 14 (1-2): 6-15
27. Millership JS. Microassay of drugs and modern measurement techniques. Paediatr Anaesth 2011; 21 (3): 197-205
28. Ter Heine R, Rosing H, Van Gorp ECM, et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867 (2): 205-12
29. US Food and Drug Administration. Guidance for industry: population pharmacokinetics, 1999 online. Available from URL: http://www.fda.gov/down loads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184. pdf Accessed 2011 Oct 27
30. Meibohm B, Laer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7 (2): E475-87 (Pubitemid 43071326)
31. Retout S, Duffull S, Mentre F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001; 65 (2): 141-51 (Pubitemid 32220157)
32. Burger D, Ewings F, Kabamba D, et al. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. Ther Drug Monit 2010; 32 (3): 369-72
33. Bartelink IH, Rademaker CMA, Schobben AFaM, et al. Guidelines on pae-diatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45 (11): 1077-97 (Pubitemid 44631388)
34. Jadhav PR, Kern SE. The need for modeling and simulation to design clinical investigations in children. J Clin Pharmacol 2010; 50 (9 Suppl.): 121S-9S
35. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28 (3): 468-73 (Pubitemid 44314939)
36. Acosta EP, Kimberlin DW. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin Pharmacol Ther 2010; 88 (5): 704-7
37. Neely MN, Rakhmanina NY. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet 2011; 50 (3): 143-89
38. Reed MD. Reversing the myths obstructing the determination of optimal age-and disease-based drug dosing in pediatrics. J Pediatr Pharmacol Ther 2011; 16: 4-13
39. Laer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 2009; 49 (8): 889-904
40. Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther 2010; 87: 270-1
41. Edginton AN, Willmann S. Physiology-based versus allometric scaling of clearance in children: an eliminating process based comparison. Paediatr Perinat Drug Ther 2006; 7: 146-53 (Pubitemid 46010017)
42. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45 (10): 1013-34 (Pubitemid 44436004)
43. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45 (9): 931-56 (Pubitemid 44299829)
44. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth 2011; 21 (3): 291-301
45. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89 (2): 259-67
46. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 2007; 21 (4): 169-75 (Pubitemid 350194376)
47. Leeder JS, Kearns GL, Spielberg SP, et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010; 50 (12): 1377-87
48. Daood M, Tsai C, Ahdab-Barmada M, et al. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008; 39 (4): 211-8
49. US Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function. Study design, data analysis, and impact on dosing and labeling, 2010 online. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM204959.pdf Accessed 2011 Oct 27
50. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtra-tion rate in full-term infants during the first year of life. J Pediatr 1984; 104 (6): 849-54 (Pubitemid 14119952)
51. Brion LP, Fleischman AR, Mccarton C, et al. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: non-invasive assessment of body composition and growth. J Pediatr 1986; 109 (4): 698-707 (Pubitemid 16028629)
52. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4 (11): 1832-43
53. Baer GR, Nelson RM, Ethics Group of the Newborn Drug Development I. Ethicalchallenges in neonatal research: summary report of the ethics group of the newborn drug development initiative. Clin Ther 2006; 28 (9): 1399-407 (Pubitemid 44585285)